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Background: The relationship of saliva with plasma protein levels makes saliva an attractive diagnostic tool. Plasma
levels of adiponectin and leptin in healthy individuals or diabetes mellitus patients have been previously reported.
Nevertheless, salivary levels of these adipocytokines in patients with metabolic syndrome (MS) have never been
investigated. This study was aimed to determine adiponectin and leptin levels in saliva and plasma from patients
with metabolic syndrome, and evaluate any correlation of these levels with MS.
Methods: Forty-six healthy and 82 MS patients were enrolled. Demographic data and blood biochemistries were
recorded. Saliva and plasma adiponectin and leptin levels were analyzed by enzyme-linked immunosorbent assay
(ELISA).
Results: Adiponectin and leptin were higher in plasma than in saliva (p < .001). Plasma adiponectin was decreased
and plasma leptin increased in patients with MS (p < .001). Salivary adiponectin and salivary leptin were not
different between healthy subjects and MS patients (p = .619 and p = .523). Correlation between salivary and plasma
adiponectin showed significant association (r = .211, p = .018) while salivary and plasma leptin had no correlation
(r = −.161, p = .069). Significant correlation was observed between the salivary adiponectin/salivary leptin ratio and
plasma adiponectin (r = .371, p < .001), but not with any component of MS. Increased triglyceride and waist
circumference were associated with risk of having a low level of plasma adiponectin (OR = 1.009; 95% CI 1.002–
1.015 and OR = 1.125; 95% CI 1.029–1.230). For leptin, body mass index and high-density lipoprotein cholesterol
(HDL-C) were associated with a high level of plasma leptin (OR = 1.621; 95% CI 1.212–2.168 and OR = .966; 95% CI
.938–.996). The OR for MS as predicted by plasma adiponectin was .928 (95% CI .881-.977).
Conclusions: This study showed that salivary adiponectin and leptin do not correlate with MS. Although
correlation between salivary and plasma adiponectin was observed, no association with MS was observed. Only
plasma adiponectin may be useful for the prediction of MS.
Keywords: Saliva, Plasma, Adiponectin, Leptin, Metabolic syndromeBackground
Metabolic syndrome (MS) is a disease that poses signi-
ficant risk of developing diabetes mellitus (DM) and
cardiovascular disease (CVD). It is indicated by the pres-
ence of three or more of the following components:
abdominal obesity, raised fasting glucose, dyslipidemia
(raised triglyceride (TG) with lowered high-density lipo-
protein cholesterol (HDL-C)), and raised hypertension.* Correspondence: supanee.tha@mahidol.ac.th
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reproduction in any medium, provided the orWaist measurement for abdominal obesity varies be-
tween gender and among different populations [1]. The
number of patients with MS is expanding worldwide.
The prevalence in developed and developing countries is
comparable, ranging from 15.2% to 43.7% [1-4].
Many of the components of MS are connected through
physiological pathways. Adiponectin, an anti-atherogenic
and anti-inflammatory adipocytokine involved in glucose
and lipid metabolism, improves insulin sensitivity [5]. Adi-
ponectin levels in plasma are inversely correlated with vis-
ceral adiposity. Lower levels of adiponectin were observed
in patients with high blood pressure, hyperglycemia, low
HDL-C, and hypertriglyceridemia, and in obese patientsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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lating adiponectin may be used as a possible biomarker
for MS [7]. Leptin, an anti-obesity adipocytokine, regulates
body weight by modifying energy levels and increasing
metabolic rate while decreasing food intake. Most over-
weight and obese patients show resistance to leptin at the
receptor level, and therefore have higher leptin levels than
non-overweight individuals [8]. Serum leptin levels in pa-
tients with MS are higher than those in healthy controls
[9]. Adiponectin and leptin levels show an inverse correl-
ation with each other [10].
The relationship between protein levels in saliva and
plasma makes saliva an attractive diagnostic tool that
could be used as an alternative to blood in tests measur-
ing biomarkers [11]. Currently, assays are available to
analyze various salivary parameters. Measurement of
adiponectin and leptin in saliva is simple, non-invasive,
and may be an acceptable alternative to plasma sam-
pling. Previous studies have reported successful meas-
urement of adiponectin and leptin in saliva from healthy
individuals or DM patients [12-15]. To the best of our
knowledge, no previous studies have analyzed the levels
of these biomarkers in saliva from patients with MS.
Thus, the aim of this study was to determine adiponec-
tin and leptin profiles from saliva and plasma in patients
with MS compared with those of healthy patients. We
aimed to measure correlations between salivary and
plasma adipocytokines in both groups to determine if an
association exists between these biomarkers and MS.
Materials and methods
Study participants
Patients being seen at the Golden Jubilee Medical Center
(Mahidol University) were randomly assessed for MS.
All participants were fully informed before completing
their written consent document. The protocol and con-
sent forms were approved by The Ethics Committee of
Mahidol University and Tokyo Medical and Dental
University, which conforms to the Helsinki Declaration
(Reference Number: MU-DT/PY-IRB2011/134.3006,
TMDU-IRB 2012/1108.860). Waist circumference was
measured, and levels of TG, HDL-C, fasting plasma glu-
cose (FPG), and blood pressure (BP) were evaluated from
patient medical chart records. MS was diagnosed when
three of the following five factors were present: (1) elevated
waist circumference (≥85 cm in Thai men and ≥80 cm in
Thai women); (2) elevated TG level (≥150 mg/dL); (3)
reduced HDL-C (<40 mg/dL in men, and <50 mg/dL in
women); (4) elevated blood pressure (systolic BP (SBP)
≥130 or diastolic BP ≥85 mmHg); and (5) elevated FPG
(≥100 mg/dL) [16].
Eighty-two patients newly diagnosed with MS and
never receiving medications were included in this study.
Patients with systemic diseases as well as those who hadreceived medications were excluded. Forty-six subjects
with healthy status according to case selection procedure
were recruited as a control group. Demographic data
were collected. The height and body weight of partici-
pants were also recorded and body mass index (BMI)
was calculated.
Plasma collection
On the same date that peripheral vein blood was drawn to
determine blood chemistries, a second blood sample was
centrifuged to obtain plasma and a 1-mL aliquot was kept
frozen (−80°C) for further adipocytokine analyses.
Saliva collection
Unstimulated whole saliva was collected from all pa-
tients. Each individual was requested to abstain from
eating, drinking, smoking, and brushing his/her teeth for
at least 60 min prior to collection. Saliva samples were
collected between 9 a.m. and 12 noon. Unstimulated
whole saliva was collected using the drooling technique.
Each subject rinsed their mouth with water before saliva
collection, then the patient was asked to swallow to
remove saliva from the mouth. The patient was seated
upright, and leaned their head forward over a test tube
with a funnel, allowing their saliva to drain into the tube.
Whole saliva (~5 mL) was obtained from each individ-
ual. During saliva collection, the test tube was placed on
ice. At the end of the collection, any remaining saliva in
the patient’s mouth was expelled into the test tube.
Saliva processing
Saliva obtained was centrifuged at 15,000 × g (MPW-65R,
MPW.Med Instrument, Warszawa, Poland) for 15 min at
4°C to remove insoluble material. Supernatant was divided
into 1-mL aliquots in pre-chilled cryotubes. The speci-
mens were immediately frozen (−80°C) until analysis.
Assay for adiponectin and leptin
Saliva and plasma were thawed at room temperature for
adipocytokine measurement by enzyme-linked immuno-
sorbent assay (ELISA). A commercial ELISA kit for hu-
man adiponectin and leptin (RayBio®, Norcross, GA) was
used and the assay was conducted according to the man-
ufacturer’s instructions with minor modification as pre-
viously reported [15]. Each sample of saliva and plasma
from the same patient was run in the same experimental
set and analyzed in duplicate. Plasma samples required
20,000-fold dilution for adiponectin and 100-fold dilu-
tion for leptin; saliva samples were analyzed without
dilution.
Data analysis
SPSS 16.0 software for Windows (SPSS Inc., Chicago,
IL) was used for statistical analyses. Descriptive statistics
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marker. All continuous variables were first assessed for
normality using the Kolmogorov-Smirnov test and bio-
marker data were positively skewed as anticipated. Results
are displayed as median with interquartile range. Com-
parison between saliva and plasma adipocytokine was per-
formed using the Wilcoxon signed-rank test. Comparison
of saliva or plasma adipocytokines and other variables
between healthy patients and patients with MS was per-
formed using the Mann–Whitney U test. Spearman’s Rho
correlation coefficients and coefficients of partial correl-
ation controlling for age, gender, and BMI were calculated
to examine relationships between saliva and plasma adipo-
cytokines and variables of MS. Logistic regression analysis
controlling for the effect of covariates was further per-
formed to ascertain the independent predictive value and
impact of variables significantly correlated with plasma
adiponectin levels, plasma leptin levels, and MS. A p value
of < .05 was considered to be statistically significant.
Results
Characteristics of the study population
One hundred and twenty-eight patients were enrolled in
this study. Eighty-two (64.06%) patients had MS. Of
these, 43 patients (52.44%) had three of five compo-
nents, 28 patients (34.15%) had four of five components,
and 11 patients (13.41%) had all five components of MS.
Patient characteristics and biomarker levels are summa-
rized in Table 1. All blood chemistries had statistically
significant differences between healthy subjects and
patients with MS (Table 1).
Adipocytokine profiles and correlation with MS
components
A Kruskal–Wallis test revealed no statistically significant
difference in the number of markers of MS across
plasma adiponectin (ϰ2 = 2.857, df = 2, p = .240) or leptin
(ϰ2 = 1.444, df = 2, p = .486), although plasma adiponec-
tin levels were likely to be decreased when components
of MS were increased. Consequently, all MS patients,
despite exhibiting three, four, or five components of MS,
were grouped together for data analysis.
Salivary and plasma levels of adiponectin and leptin are
shown in Table 1. Adiponectin and leptin levels in plasma
were significantly higher than those in saliva, both in
healthy subjects and patients with MS (p < .001). Plasma
adiponectin levels were decreased significantly in patients
with MS compared with healthy individuals (p < .001) while
salivary adiponectin levels were not significantly different
(p = .619). In contrast to adiponectin, plasma leptin levels
were significantly elevated in patients with MS compared
with healthy individuals (p < .001). Salivary leptin levels
showed no statistically significant difference compared with
those of healthy persons (p = .523). Female patients in ourstudy had higher plasma adiponectin and leptin levels com-
pared with the male participants (p < .001, p = .004 respect-
ively), while no significant difference of salivary adiponectin
(p = .341) and leptin (p = .462) levels between male and fe-
male participants was observed. Spearman’s Rho correlation
between salivary and plasma adiponectin levels showed sig-
nificant association (r= .179, p = .043), and significance in-
creased after controlling for age, gender, and BMI (r = .211,
p = .018) (Figure 1a). Salivary and plasma leptin levels
produced no significant correlation (r = −.161, p = .069)
(Figure 1b), even after controlling for age, gender, and
BMI (r = .000, p = .997).
When determining each component of MS, the corre-
lations between plasma adiponectin and TG, HDL-C,
diastolic blood pressure (DBP), and waist circumference
were significant after adjusting for age, gender, and BMI,
while salivary adiponectin levels did not correlate with
age, gender, BMI, or any component of MS (Table 2).
The relationship between plasma leptin, HDL-C, and
waist circumference was also significant after adjusting
for age, gender, and BMI, while salivary leptin levels did
not correlate with any components (Table 2).
To comprehensively define other associations, the corre-
lations of plasma adiponectin/plasma leptin, plasma adi-
ponectin/salivary adiponectin, and salivary adiponectin/
salivary leptin ratios were determined with BMI and each
component of MS. Interestingly, plasma adiponectin/
plasma leptin ratio were significantly correlated with all
five components of MS (p < .05; data not shown in table).
Looking specifically at salivary adipocytokines, the saliv-
ary adiponectin/salivary leptin ratio was also significantly
associated with plasma adiponectin (r = .206, p = .019)
and waist circumference (r = .251, p = .004). After con-
trolling for age, gender, and BMI, a strongly significant
correlation was still observed between the salivary adi-
ponectin/salivary leptin ratio and plasma adiponectin
(r = .371, p < .001).
Association of adipocytokines with MS
To eliminate confounding effects, logistic regression ana-
lysis was performed. We divided the participants to create
dichotomous groups based on low and high levels of
plasma adiponectin and plasma leptin, using the median
level of both adipocytokines as a cut-off point (18.488 μg/
mL for adiponectin and 9.525 ng/mL for leptin). When low
plasma adiponectin was used as a dependent variable, every
unit increase of TG and waist circumference was signifi-
cantly associated with risk of having low plasma adipo-
nectin (odd ratio (OR) = 1.009; 95% confidence interval
(CI) 1.002–1.015, and OR = 1.125; 95% CI 1.029–1.230,
respectively) (Table 3). The relationship between leptin
and components of MS was analyzed in the same man-
ner using high plasma leptin as a dependent variable.
BMI was associated with high plasma leptin by OR
Table 1 Characteristics of the study population and biomarker levels
Healthy subjects (n = 46) Patients with metabolic syndrome (n = 82) p-value
Total Male Female Total Male Female
Gender 46 13 33 82 40 42 .024
Age (years) 44.50 52.00 44.00 48.00 49.00 48.00‡ .013
(38.75-53.00) (41.50-58.50) (38.00-49.00) (43.75-58.00) (44.00-58.75) (42.75-55.75)
Body mass index (kg/m2) 21.82 22.00 21.81 27.26 26.97# 27.28# <.001
(20.22-22.89) (20.97-23.55) (19.42-22.81) (24.56-29.53) (24.68-29.20) (23.96-30.10)
Triglyceride (mg/dL) 73.00 72.00 73.00 181.50 205.50# 165.00# <.001
(57.75-89.00) (64.00-95.00) (56.50-86.50) (136.00-290.50) (141.50-304.00) (128.00-244.00)
High density lipoprotein cholesterol
(mg/dL)
- 60.00 65.00 - 44.50# 44.50# <.001
(53.00-65.00) (60.00-75.50) (35.25-51.75) (40.75-49.25)
Low density lipoprotein cholesterol
(mg/dL)
105.50 115.00 100.00 159.50 154.50# 162.50# <.001
(91.25-117.25) (101.00-123.00) (88.50-116.50) (141.00-184.00) (140.25-188.00) (141.75-184.00)
Total cholesterol (mg/dL) 182.00 191.00 178.00 233.00 232.00# 235.00# <.001
(169.75-193.25) (177.50-195.00) (165.50-191.50) (210.25-260.00) (212.25-259.75) (207.75-260.25)
Systolic blood pressure (mmHg) 117.00 118.00 116.00 134.00 135.00# 133.00# <.001
(109.00-125.25) (109–126.50) (109.00-125.00) (119.75-141.25) (120.50-141.75) (117.75-141.25)
Diastolic blood pressure (mmHg) 73.00 78.00 72.00 85.50 88.00# 81.50# <.001
(68.75-79.25) (70.50-80.50) (67.50-78.00) (79.00-91.25) (82.25-95.00) (74.75-87.25)
Fasting plasma glucose (mg/dL) 90.00 92.00 90.00 102.50 107.50# 100.00# <.001
(87.00-94.00) (89.00-94.00) (86.00-94.00) (96.00-119.25) (99.00-123.00) (92.75-108.00)
Waist circumference (cm) - 81.00 75.00 - 91.00# 90.50# <.001
(73.50-82.00) (69.50-78.50) (86.00-95.75) (86.75-94.50)
Plasma adiponectin (μg/ml) 32.24 20.21 33.38 14.01 13.69‡ 14.21# <.001
(17.96-46.84) (9.842-41.33) (21.13-48.64) (8.09-14.010) (5.38-20.79) (9.66-28.07)
Salivary adiponectin (μg/ml) 2.92 3.46 1.93 2.78 3.51 1.88 .619
(7.91-6.23) (1.74-7.03) (5.62-4.38) (1.05-6.48) (1.49-9.09) (8.17-6.25)
Plasma leptin (ng/ml) 6.04 2.39 7.39 13.23 7.37# 21.70# <.001
(2.92-9.24) (1.17-3.58) (5.13-10.38) (6.50-22.13) (4.85-11.40) (14.77-28.59)
Salivary leptin (pg/ml) 33.80 38.51 31.21 34.88 43.17 29.59 .523
(14.66-102.80) (18.71-104.55) (11.71-103.89) (17.07-54.77) (14.57-59.88) (17.34-48.98)
All data presented as median (25th-75th percentile).
#Significant difference from healthy same gender (p < .001).
‡Significant difference from healthy same gender.
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HDL-C level was significantly associated with 3.4% de-
creased risk of having high plasma leptin (OR .966; 95% CI
.938–.996). Additionally, high plasma leptin in female ver-
sus male patients persisted after the data was adjusted for
other confounders (Table 4). Salivary adiponectin, salivary
leptin, and the salivary adiponectin/salivary leptin ratio
were not significant determinants for either plasma adipo-
cytokine (Tables 3 and 4).
Finally, to assess the variables that could predict MS
outcome, apart from standard criteria, logistic regression
analysis was performed using several different models
(Table 5). The fully adjusted OR for MS, as predicted byplasma adiponectin and controlling for age, gender, and
BMI was .928 (95% CI, .881–.977; p < .05), indicating that
there was a 7% decrease in the odds of having MS for each
1 μg/mL increase in plasma adiponectin. This model
showed that age, BMI, and plasma adiponectin levels were
significantly associated with a risk of MS, and could be
used as the prognostic markers for MS by the equation:
Log (odd) = −18.450 + .089(age) + .666(BMI) − .075(plasma
adiponectin level).
Discussion
Adiponectin and leptin were successfully detected in the
saliva of patients with MS, although lower levels were
Figure 1 Scatter plot demonstrating the association between salivary and plasma adiponectin levels (r = .211, p = .018) (a), salivary and
plasma leptin levels (r = −.161, p = .069) (b), adjusting for age, gender, and BMI. Values of salivary and plasma adiponectin and leptin have
been log transformed.
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ponectin, as well as the salivary adiponectin/salivary
leptin ratio, was significantly correlated with its plasma
levels, while salivary leptin levels were not. Between
patients with MS and healthy individuals, significant
differences were seen in adiponectin and leptin levels
from plasma, but not from saliva. The levels of salivary
adiponectin and leptin were in identical ranges to those
found in previous studies that measured the levels in
healthy subjects or in DM patients [13,14]. Our findingof a correlation between salivary and plasma adiponec-
tin in this study is in agreement with previously pub-
lished reports [13,17,18]. Toda et al. found that there
was a significant correlation between plasma and saliv-
ary adiponectin levels in an older group of healthy pa-
tients [13]. Similar results have been recently reported
in the studies of Mamali et al. and Akuailou et al., al-
though the measured values of adiponectin were differ-
ent, possibly due to saliva sample dilution and the
characteristics of the patients [17,18].
Table 2 Coefficients of bivariate and partial correlation between salivary and plasma adipocytokine values and various biomarkers of metabolic syndrome,
controlling for age, gender (Model 1) and age, gender and BMI (Model 2)

































Age NS - - NS - - NS - - NS - -
Gender r = .259 p = .004 - - - - - r = .484 p < .001 - - - - -
Body mass index r = −.315 p < .001 r = −.197
p = .027
- NS NS - r = .557 p = .000 r = .700
p < .001
- NS NS -




NS NS NS r = .334 p < .001 r = .316
p < .001
NS NS NS NS
High density lipoprotein
cholesterol









Systolic blood pressure NS r = −.216
p = .015
NS NS NS NS NS r = .251
p = .005
NS NS NS NS




NS NS NS NS r = .282
p = .001
NS NS NS NS
Fasting plasma glucose r = −.352 p < .001 NS NS NS NS NS r = .175 p = .048 NS NS NS NS NS






























Table 3 Association of demographic variables, component of metabolic syndrome, and salivary adiponectin with low
levels of plasma adiponectin in logistic regression model
Low level of plasma adiponectin (≤ 18.488 μg/ml)









Age (years) 49.00 (43.25-58.00) 45.00 (39.00-53.00) .967 (.932-1.003) .075 .949 (.900-1.001) .055
Gender
Male (reference) 22 (17.19%) 31 (24.22%)
Female 42 (32.81%) 33 (25.78%) .558 (.274-1.136) .108 .937 (.356-2.466) .895
Body mass index (kg/m2) 23.45 (21.27-27.02) 25.30 (23.25-28.43) 1.124 (1.028-1.229) .010* .849 (.705-1.022) .084
Triglyceride (mg/dL) 91.50 (62.00-154.50) 178.50 (104.50-293.00) 1.009 (1.005-1.014) <.001* 1.009 (1.002-1.015) .008*
High density lipoprotein cholesterol
(mg/dL)
59.00 (47.25-66.00) 45.00 (37.25-55.75) .969 (.946-.993) .012* 1.006 (.978-1.035) .667
Systolic blood pressure (mmHg) 127.00 (113.50-137.00) 126.50 (116.25-138.75) 1.007 (.984-1.030) .565 .979 (.937-1.023 .344
Diastolic blood pressure (mmHg) 80.00 (72.00-85.75) 82.00 (75.00-88.75) 1.037 (1.000-1.075) .051 1.002 (.933-1.075) .962
Fasting plasma glucose (mg/dL) 94.00 (88.25-101.75) 99.50 (91.25-114.75) 1.008 (.999-1.017) .082 1.003 (.993-1.013) .538
Waist circumference (cm) 82.00 (74.25-91.00) 88.00 (82.25-94.00) 1.071 (1.029-1.114) .001 1.125 (1.029-1.230) .010*
Salivary adiponectin (μg/ml) 3.34 (1.05-6.49) 1.94 (.85-6.16) 1.000 (1.000-1.000) .157 1.000 (1.000-1.000) .231
Data presented as median (25th-75th percentile).
*statistical significance.
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have been previously reported in other studies [19,20].
As in the present study, Aydin et al. saw that the levels
of salivary leptin were almost the same as in plasma; no
significant correlation between plasma leptin and saliv-
ary leptin was shown in all of the healthy patients in the
study [21]. Nevertheless, others have seen a strong
correlation between salivary and plasma leptin in healthy
individuals, with this correlation significantly higher inTable 4 Association of demographic variables, components o
of plasma leptin in logistic regression model




Age (years) 46.50 (42.00-54.75) 48.00 (40.25-
Gender
Male (reference) 38 (29.69%) 15 (11.72
Female 26 (20.31%) 49 (38.28
Body mass index (kg/m2) 22.81 (21.18-24.74) 27.31 (23.87-
Triglyceride (mg/dL) 89.00 (68.25-201.25) 160.50 (104.50
High density lipoprotein cholesterol
(mg/dL)
60.00 (45.50-66.75) 47.50 (40.00-
Systolic blood pressure (mmHg) 125.50 (114.25-136.00) 128.00 (117.00-
Diastolic blood pressure (mmHg) 80.00 (71.25-89.00) 81.00 (75.00-
Fasting plasma glucose (mg/dL) 94.00 (88.25-106.00) 99.50 (92.25-1
Waist circumference (cm) 81.00 (74.00-86.00) 90.50 (86.00-
Salivary Leptin (pg/ml) 45.26 (13.92-92.06) 30.19 (16.28-
Data presented as median (25th-75th percentile).
*statistical significanceplasma than saliva [12,22]. Dissimilar results in the cor-
relation between salivary and plasma leptin levels might
be explained by the laboratory method used (RIA vs
ELISA), molecular structure of leptin, or the expression
and secretion of leptin by the salivary glands themselves
[12,22,23]. Furthermore, Randeva et al. reported circa-
dian variation in the levels of salivary leptin. It reached
low levels in the morning, the time at which saliva samples
were collected in this study [12]. Thus, concentrations off metabolic syndrome, and salivary leptin with high levels








56.00) 1.010 (.975-1.047) .581 1.043 (.971-1.120) .246
%)
%) 4.774 (2.224-10.247) <.001* 91.224 (13.397-621.151) <.001*
29.96) 1.368 (1.207-1.549) <.001* 1.621 (1.212-2.168) .001*
-226.50) 1.002 (.999-1.005) .124 .998 (.993-1.003) .358
55.75) .970 (.947-.994) .015* .966 (.938-.996) .024*
140.00) 1.012 (.989-1.036) .310 .973 (.906-1.044) .444
87.00) 1.007 (.973-1.043) .684 1.037 (.942-1.142) .458
07.75) .994 (.986-1.002) .142 .987 (.969-1.005) .143
94.75) 1.109 (1.060-1.161) <.001* 1.099 (.978-1.236) .113
50.76) .999 (.993-1.004) .643 1.004 (.995-1.013) .356




Crude OR (95% CI) Presence of metabolic syndrome
Adjusted OR (95% CI)
Model 1 Model 2 Model 3
Age 1.047 (1.005-1.091)‡ 1.071 (1.006-1.140)‡ 1.115 (1.031-1.206)# 1.093 (1.008-1.186)‡
Gender (female) .414 (.191-.897)‡ .903 (.278-2.933) 1.089 (.291-4.068) .333 (.049-2.239)
Body mass index 2.504 (1.751-3.579)## 2.529 (1.725-3.708)## 2.393 (1.615-3.546)## 1.947 (1.280-2.961)#
Plasma adiponectin .943 (.918-.969)## .928 (.884-.974)## .928 (.881-.977)#
Salivary adiponectin 1.000 (1.000-1.000) 1.000 (1.000-1.000) 1.000 (1.000-1.000)
Plasma leptin 1.179 (1.094-1.271)## 1.135 (.976-1.320)
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concentrations, as is seen with adiponectin. Autonomous
production, structure modification, secretory pattern, or
varying patient metabolism could reflect the discrepancies
in the level and correlation of salivary and plasma leptin.
Regarding the correlation of salivary adiponectin and
leptin with age or BMI, only two previous reports have
discussed salivary adiponectin [13,17]. Similar to our
study, others found salivary adiponectin was not signifi-
cantly correlated with either age or BMI. Contrary to our
study, salivary leptin correlation with BMI was described
by a single previous study [12]. One interesting observa-
tion from our work was that the salivary adiponectin/
salivary leptin ratio was significantly associated with waist
circumference, although this association disappeared after
controlling for age, gender, and BMI. No previous studies
have documented this aspect, so it would be interesting
for further studies to clarify this possible association of the
salivary adiponectin/salivary leptin ratio with waist cir-
cumference. In addition, no previous reports directly
investigated about salivary adiponectin and leptin with
alcohol consumption, smoking habit or education level.
However from our data analysis (data not shown), no sta-
tistically significant difference between healthy subjects
and patients with metabolic syndrome according to these
confounding factors and no correlation of these con-
founders with salivary levels of adipocytokines were found.
When we considered saliva and plasma adipocytokines
between male and female patients, female patients in
our study had higher plasma adiponectin and leptin
levels compared with the male patients. Although
slightly higher salivary adiponectin and leptin levels in
men were observed in this study, no significant differ-
ence in salivary leptin and salivary adiponectin levels
was observed between genders. Results showing that
both saliva and plasma leptin levels are higher in female
patients compared with male patients have beendocumented [12,21]. However, in the study by Randeva
et al., the ratios of salivary and plasma leptin concentra-
tions were higher in men [12]. Sex steroid hormones,
body fat content or genetic differences might be respon-
sible for this difference observed between men and
women [12]. Despite this potential caveat, our findings
extend the data of adiponectin and leptin levels in saliva
of patients with MS.
Owing to the correlation of plasma adiponectin and
leptin with MS components, this study found that
plasma adiponectin and plasma leptin had distinct corre-
lations with TG, HDL-C, DBP, and waist circumference.
These results are consistent with many previous reports
[24-30]. Others have shown there is a positive correl-
ation of plasma adiponectin and HDL-C, and an inverse
relationship between this adipocytokine with TG, waist
circumference, and low-density lipoprotein-cholesterol
(LDL-C) [31]. Similar to the data from Kawamoto et al.
that showed an inverse association of TG and adiponec-
tin [32], TG and waist circumference in our study were
associated with the risk of having a low level of plasma
adiponectin, while HDL-C was inversely associated with
a high level of plasma leptin. Identical results were re-
ported in a study by Wannamethee et al. where in-
creased leptin levels were independently associated with
a decrease in HDL-C [28]. Existing data for correlation
between plasma adiponectin and age are controversial.
Plasma adiponectin levels are reported as lower, un-
changed, or higher as age increases [13,33,34], whereas
plasma adiponectin levels were negatively correlated
with BMI, and were higher in female patients than in
male patients [25]. The present study noted a significant
inverse association of plasma adiponectin levels with
BMI, being higher in women than in men, while no as-
sociation was observed with age. These results suggest
that age, gender, and BMI could be the driving forces
behind the correlations. Similar to previous studies, we
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BMI with each component of MS [35-37]. The effect of
sex hormones might explain this discrepancy, as it has
been hypothesized that androgen inhibits adiponectin
secretion [38].
Our results are in agreement with those of Schutte
et al., who reported significant correlations of plasma
adiponectin and plasma leptin with mean arterial pres-
sure that disappeared after the effects of age and BMI
were taken into account [37]. Moreover, our study
showed that FPG was clearly not associated with plasma
adiponectin and plasma leptin after adjustments for age,
gender and BMI. While previous studies have shown
that there are strong associations between low adipo-
nectin levels and impaired FPG or insulin resistance,
independent of age, gender, or BMI [24,29,33,34,39,40],
meta-analysis revealed that higher adiponectin levels are
associated with a lower risk of type 2 DM [41]. A con-
troversial correlation between plasma leptin and BP and
impaired fasting glucose or insulin resistance was pub-
lished [27-29,40,42], however Wannamethee et al. found
no association of plasma leptin and blood glucose, BP,
and total cholesterol, which was identical to the results
of this study and those of Wang et al. [28,29]. Contro-
versies about correlations between adiponectin, leptin,
and blood glucose might be due to different sample pop-
ulations, and future studies are necessary to verify these
results. Finally, the logistic regression model in this
study showed that age, BMI, and plasma adiponectin,
not salivary adiponectin, levels were significantly associ-
ated with the presence of MS. Similar to previous studies
showing plasma adiponectin was a strong predictor of
MS in both men and women [7,24,25,43].
The findings of the present study should be considered
as preliminary, and subject to some limitations. First, this
study was designed to be cross-sectional, which limits its
ability to eliminate causal relationships between salivary
and plasma adipocytokines and MS. Longitudinal studies
are required to validate the diagnostic usefulness of saliva
and plasma adiponectin and leptin for the detection of
MS. Second, the sample size was not large; the patients
who had four or five components of MS were fewer than
those who had three components. This might reflect the
insignificant difference of plasma adiponectin or leptin
levels among each component group, a finding that is dif-
ferent from previous studies where plasma adiponectin
levels decreased as components of MS increased [24,25],
with leptin showing the opposite trend [33]. Our results
need to be confirmed longitudinally and with a greater
number of samples in order to find strong associations.
Third, selection bias should be considered. The study
group is not strictly a random population sample, being
influenced by selection criteria and responses that might
bias the results obtained from patients with MS versushealthy individuals. Last, another restriction is the lack of
data for the homeostasis model assessment of insulin
resistance (HOMA-IR). Owing to a laboratory limitation,
adequate analysis for HOMA-IR has not been achieved.
Conclusions
The present study suggests that measurement of adipo-
nectin and leptin from saliva has uncertain accuracy as
an alternative to plasma sampling for analytical fluid in
patients with MS. Although correlation between salivary
adiponectin and plasma adiponectin was presented, no
association with MS components was observed with sal-
iva samples. In particular, the reliability of salivary leptin
as a biomarker was questionable. Clinical use of these
salivary biomarkers currently has limitations, and needs
further study before replacing plasma sampling. Measur-
ing plasma adiponectin and leptin is still preferable.
Plasma adiponectin may be a useful adjunct for the pre-
diction of MS, as we observed a stronger association
with MS than plasma leptin in this specific group of
Thai patients with MS.
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